Price Disclosure
Page last updated: 20 January 2021
Outcomes from Price Disclosure
- 2021 April Cycle (Tenth Remove Originator Cycle)
- 2020 October Cycle (Ninth Remove Originator Cycle)
- 2020 April Cycle (Eighth Remove Originator Cycle)
- 2019 October Cycle (Seventh Remove Originator cycle)
- 2019 April Cycle (Sixth Remove Originator cycle)
- 2018 October Cycle (Fifth Remove Originator cycle)
- 2018 April Cycle (Fourth Remove Originator cycle)
- 2017 October Cycle (Third Remove Originator cycle)
- 2017 April Cycle (Second Remove Originator cycle)
- 2016 October Cycle (First Remove Originator cycle)
- 2016 April Cycle (Fourth SPD)
- 2015 October Cycle (Third SPD)
- 2015 April Cycle (Second SPD)
- 2014 October Cycle (First SPD)
Indicative Prices - Disclosure Cycles
Indicative price disclosure-related price changes are being made available in advance of the effective date to assist companies and other stakeholders. They will come into effect under the National Health Act 1953 and the National Health (Pharmaceutical Benefits) Regulations 2017 and have already been announced publicly - see 'Outcomes from Price Disclosure (SPD)'.
These prices are indicative only and may change if there are changes in prices or listings before the Reduction Day (e.g., lower price / pricing quantity changes).
Indicative prices are published for F2 combination drugs that are taking a direct price disclosure reduction.
Indicative prices are not published for any medicines that are:
- not taking a price disclosure reduction in the respective cycle;
- new brands after the date of publication;
- brands with other price changes on the reduction day;
- combination drugs taking flow-on price disclosure reductions; or
- F2 combination drugs taking flow-on price disclosure reductions.
Those other prices will be available publicly on the Effective Day.
- Indicative 1 April 2021 Prices – 2021 April Cycle
- Indicative 1 October 2020 Prices – 2020 October Cycle
- Indicative 1 April 2020 prices – 2020 April cycle
- Indicative 1 October 2019 prices - 2019 October cycle
- Indicative 1 April 2019 prices - 2019 April cycle
- Indicative 1 October 2018 prices - 2018 October cycle
- Indicative 1 April 2018 prices - 2018 April cycle
- Indicative 1 October 2017 prices - 2017 October cycle
- Indicative 1 April 2017 prices - 2017 April cycle
- Indicative 1 October 2016 prices - 2016 October cycle
- Indicative 1 April 2016 prices - 2016 April cycle
- Indicative 1 October 2015 prices - 2015 October cycle
- Indicative 1 April 2015 prices - 2015 April cycle
- Indicative 1 October 2014 prices - 2014 October cycle
Confirmation of New Prices – Disclosure Cycles
The spreadsheets below set out price disclosure related price changes effective on the reduction day. This includes all the levels of PBS prices previously published under the Indicative Prices heading (above).
These price disclosure related changes are being made available in advance of the effective date to assist companies. They come into effect under the National Health Act 1953 and have already been announced publicly (refer to Outcomes from Price Disclosure section above).
- Confirmed 1 October 2020 prices – 2020 October cycle
- Confirmed 1 April 2020 prices – 2020 April cycle
- Confirmed 1 October 2019 prices – 2019 October cycle
- Confirmed 1 April 2019 prices – 2019 April cycle
- Confirmed 1 October 2018 prices – 2018 October cycle
- Confirmed 1 April 2018 prices – 2018 April cycle
- Confirmed 1 October 2017 prices – 2017 October cycle
- Confirmed 1 April 2017 prices – 2017 April cycle
- Confirmed 1 October 2016 prices – 2016 October cycle
- Confirmed 1 April 2016 prices - 2016 April cycle
- Confirmed 1 October 2015 prices - 2015 October cycle
- Confirmed 1 April 2015 prices – 2015 April cycle
- Confirmed 1 October 2014 prices – 2014 October cycle
Brand Price Reductions and Savings to Patients – Disclosure Cycles
The spreadsheets below set out brand level price reductions and potential individual savings to non-concessional patients effective on the reduction day mentioned.
This information is made available to assist patients with understanding how much they may save on their prescription medication as a result of the latest round of price disclosure price reductions.
- 2020 October Cycle – Brand Price Reductions and Savings to Patients
- 2020 April Cycle – Brand Price Reductions and Savings to Patients
- 2019 October Cycle – Brand Price Reductions and Savings to Patients
- 2019 April Cycle – Brand Price Reductions and Savings to Patients
- 2018 October Cycle – Brand Price Reductions and Savings to Patients
- 2018 April Cycle – Brand Price Reductions and Savings to Patients
- 2017 October Cycle – Brand Price Reductions and Savings to Patients
- 2017 April Cycle – Brand Price Reductions and Savings to Patients
Reference documents
Primary Sources
- Drugs subject to Price Disclosure
- Drugs and manners of administration that meet the 42 month clock (for a 30% Unadjusted Price Reduction) for the 2021 April Cycle
- Drugs and manners of administration that meet the 30 month clock (for an originator removal calculation) for the 2021 April Cycle
- Price Disclosure Cycles Table - dates for first cycles based on the month a drug/MoA became subject to price disclosure (PDF 72 KB) - (Word 25 KB)
- Formulary Allocations
- Items Exempt from Statutory Price Reductions
- National Health Act 1953
- National Health (Pharmaceutical Benefits) Regulations 2017
Explanatory Materials
- Fact Sheet - 30% Unadjusted Price Reduction
- Price Disclosure - 42 Month Clock Examples (PDF 256KB) - (Word 68KB)
- Fact Sheet - Remove Originator
- Price Disclosure Arrangements Procedural and Operational Guidelines (from June 2016) (PDF 633 KB) - (Word 386 KB)
- 2017 Information Session (August/September) – PBS Pricing and Price Disclosure presentation (PDF 2.7MB)
- 2017 Information Session (March) – PBS Pricing and Price Disclosure presentation (PDF 417KB)
- 2016 Information Session – Recent PBS Statutory Pricing Changes presentation (PDF 612KB)
- 2015 Price Disclosure Changes - Fact Sheet
- 2015 Price Disclosure Changes - Removal of Originator Brand Sample Price Disclosure calculation (1 October 2016 reduction day onward) (PDF 121KB) – (Word 127KB)
- Fact Sheet - Differences between IMS Profits Data & Disclosed Data (PDF 96 KB) - (Word 24 KB)
- Fact Sheet - Price Disclosure and Premiums (PDF 306 KB) - (Word 33 KB)
- Price Disclosure Dispute Resolution Administrative Process
- SPD Explanation of Price Disclosure Method (for 1 October 2014 reduction day onward) (PDF 20KB) - (Word 45KB)
- SPD Sample Price Disclosure calculation (for 1 October 2014 reduction day onward) (PDF 85KB) - (Word 55KB)
- SPD Price Disclosure Presentation slides - 2014 ARCS Scientific Congress, Canberra (PDF 843 KB) - (Word 477 KB)
- SPD Amendments Presentation slides - Stakeholder Information Session, 6 December 2013 (PDF 677 KB) - (Word 29 KB)
- SPD Amendments Supplementary Questions and Answers - Stakeholder Information Session, 6 December 2013 (PDF 676 KB) - (Word 29 KB)
- SPD Amendments Frequently Asked Questions (PDF 445 KB) - (Word 33 KB)
- SPD Amendments Factsheet - Drugs / MoAs subject to Price Disclosure - current and new cycles (alphabetically) (PDF 191 KB) - (Word 87 KB)
- SPD Amendments Factsheet - Current EAPD cycles transition to SPD (PDF 539 KB) - (Word 31 KB)
- Price Disclosure Arrangements Procedural and Operational Guidelines (pre June 2016) (PDF 614 KB) - (Word 394 KB)
Archived Material
- Price Disclosure (EAPD) - (started December 2010; covers reductions to August 2014)
- Price Disclosure (pre - 1 December 2010)